Hologic
(Nasdaq: HOLX)
today announced it completed its $310 million acquisition of Endomagnetics.
The acquisition was previously announced in April this year. It adds Endomag’s wireless breast surgery localization and lymphatic tracing solutions to Hologic’s breast surgery portfolio. It gives breast surgeons and radiologists an expanded range of options and enhanced user experience.
“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” said Erik Anderson, president of Breast and Skeletal Health Solutions at Hologic. “With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”
Endomag makes products like the Magseed marker for magnetic tissue localization before surgery. It also develops the Magtrace lymphatic tracing injectable for breast cancer staging and the Sentimag platform that supports localization and lymphatic tracing.
“We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians,” Endomag CEO Eric Mayes said. “As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”
